A Phase I Study of G3139 Subcutaneous in Solid Tumors
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
Genasense® is currently administered to subjects in clinical studies as a multiple-day
continuous intravenous infusion. Subjects are treated on an outpatient basis and carry a pump
that delivers the drug through a peripheral or central intravenous line. The route of
administration limits the convenience of treatment, and catheter-related complications have
been reported. This study is designed to evaluate the pharmacokinetics and safety of G3139
administered by subcutaneuous injection.